The primary genetic markers used for glioma taxonomy are now considered isocitrate dehydrogenase (IDH) 1 and 2 mutation status, 1p/19q co‐deletion, H3F3A alterations, ATRX gene mutations, O6‐Methylguanine‐DNA Methyltransferase (MGMT) promoter methylation status, loss of CDKN2A, epidermal growth factor receptor (EGFR) amplification, a combined gain of chromosome 7 and loss of chromosome 10, and TERT promoter pathogenic variants. This evidence concerns the gene MGMT and central nervous system cancer.